Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.
At a glance
For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.
- Primary source
- MarketWatch.com - Top Stories — Read original article
- Published
- Topic
- Markets
For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.
This summary comes from MarketWatch.com - Top Stories. Read the full article at the original source.
References
More in Markets
Why SpaceX’s stock is surging — and lifting the broader AI universe along with it
SpaceX just gave Wall Street a big reason to believe in the artificial-intelligence boom as demand for its computing power is off the charts.
AT&T shrugs off SpaceX fears with its own large haul of new internet subscribers
AT&T’s fiber business was the star of the show in Wednesday’s third-quarter earnings report.
Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next
Unlike bear-market bottoms, which typically end with a spasm of despair as traders throw in the towel, bull-market tops are far more gradual and less dramatic.
Here’s what matters most to Tesla investors heading into earnings
Financial results are somewhat of a sideshow for an investor base eagerly awaiting updates on robotaxis, robots — and the cost of all that.